Doxycycline treatment for breast cancer in early stages

In 2015, Michael Lisaanti reported that antibiotics that aim at mitochondria can exterminate cancer stem cells for several types of cancer. In other words, it is possible to "treat cancer like an infectious disease". ^{2 They first examined cancer stem cells from several types of tumor and "identified a preserved phenotypical weak point - a strict dependency on the mitochondrial biogenesis for the clonal expansion and the survival of cancer cells".}

The simple addition of vitamin C and Berberin during treatment with doxycycline could increase the anti -cancer effect.

Your analysis showed that mitochondria of stem cells could be the Achilles heel of stem cells. In the awareness that several classes of antibiotics inhibit the mitochondrial biogenesis, they next identified a list of medication, the cancer stem cells in 12 different cancer cell lines and over 8 different types of tumor (i.e. breast, ducales carcinoma in sit, eggstop, prostate, lung), pancreatic, melanoma, melanoma, melanoma, Glioblastom). ^{2 In the same year, these researchers DOXYCYCLIN identified as the preferred drug to combat mitochondria of cancer stem cells.}

The US Food and Drug Administration first approved Doxycyclin as a broadband antibiotic in 1967. The standard dose is 200 mg/day. Remember that mitochondria are offspring in the evolutionary sense and remain sensitive to antibiotics that are used more often to inhibit bacterial growth.

doxycycline is already used to treat infections in cancer patients, and there are case reports on unexpected remissions, especially in lymphomas. ^5.6

described in April 2017 Zhang et al. The effect of doxycycline when inhibiting the transitional steps from stem cell phenotypes to breast cancer.

In June 2017, this research took a turn that will find many of us fascinating: The group of Lisantis reported that the effect of doxycycline in combination with vitamin C and Berberin in Vitro is optimized. (The breast cancer patients in the study checked here only received doxycycline. Vitamin C and Berber were not included in the study protocol.) Doxycycline is so effective in the oppression of cancer stem cell populations that it creates high selection pressure that synchronizes the surviving cancer cell to a predominantly glycolytic Phenotype, which leads to metabolic inflexibility. They identified 2 natural substances (ie vitamin C, Berberin) and 6 clinically approved medication (i.e. Atovaquon, Irinotecan, Sorafenib, Nicloroquin, Chloroquin, Stiripentol) that aim to do the doxycycline-resistant CSC population. This combination strategy eliminates surviving cancer cells, according to the researchers "a simple pragmatic solution for the possible development of a doxycycline resistance in cancer cells". ^{8 This earlier in-vitro work indicated that Doxycyclin not only inhibits CSCs, but may be best is combined that use the metabolic inflexibility, such as vitamin C and Berberin. 8}

the small clinical study, which is discussed in this review, was published. This pilot study suggests that Doxycyclin can reduce the "tribes" of tumors in women with breast cancer in frequently prescribed doses.

These results indicate effectiveness, but do not prove. The observed significant decrease in "stemness" is not proof that Doxycyclin reduces the risk of a new occurrence or a slow progression of advanced cancer in the real world. In view of DOXYCYCLIN's security profile, however, it is tempting to apply this treatment strategy before final evidence is published. It is noteworthy that a publication of April 2019 indicated that the addition of azithromycin could further improve the effectiveness of a combination of doxycycline and vitamin C.

These publications suggest some obvious implications. Patients occasionally take treatment with doxycycline for the treatment of infections. This could be a useful opportunity. The simple addition of vitamin C and Berber during treatment with doxycycline could increase the anti -cancer effect. There is no published evidence that this reduces the risk of cancer or recurring, but could it harm?

Such prophylaxis could be particularly useful in patients who were previously treated for cancer and in our opinion, whose recurrence is caused by cancer stem cells. Glioblastoma and ovarian cancer come to mind.

In recent years, some practitioners have promoted treatment strategies that are the opposite of Lisantis approach. The consideration is that mitochondrial damage is responsible for the progression of cancer, and therefore dietary supplements that have been selected to repair mitochondrial damage should be an advantage. ^{10 These two approaches are in such direct contrast to each other that both ideas cannot be true. It is possible that the prevention of cancer contains the preservation of mitochondria, while the presence of an established cancer should be regarded as a significantly different condition for the cells and their mitochondria.}

In an article in August 2019, oxidative phosphorylation itself is identified as a potential therapeutic goal for cancer therapy. Based on published evidence that are available at this point, Lisanti's argument that mitochondrial biogenesis attacks is convincing as soon as cancer stem cells are present. It is certainly better proven than all suggestions that the nutrition and promotion of mitochondrial biogenesis is useful, even if the latter appears philosophically more congruent to Medicatrix Naturae .